DENTSPLY SIRONA Inc (XRAY) Shares Sold by Bartlett & Co. LLC
Bartlett & Co. LLC lessened its position in DENTSPLY SIRONA Inc (NASDAQ:XRAY) by 4.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 103,114 shares of the medical instruments supplier’s stock after selling 4,325 shares during the quarter. Bartlett & Co. LLC’s holdings in DENTSPLY SIRONA were worth $6,788,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Federated Investors Inc. PA grew its stake in DENTSPLY SIRONA by 258.6% during the 2nd quarter. Federated Investors Inc. PA now owns 5,486 shares of the medical instruments supplier’s stock worth $356,000 after purchasing an additional 3,956 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new position in DENTSPLY SIRONA during the 2nd quarter worth $764,000. Commonwealth Bank of Australia grew its stake in DENTSPLY SIRONA by 19.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 260 shares in the last quarter. Teachers Advisors LLC grew its stake in DENTSPLY SIRONA by 0.5% during the 2nd quarter. Teachers Advisors LLC now owns 342,742 shares of the medical instruments supplier’s stock worth $22,223,000 after purchasing an additional 1,616 shares in the last quarter. Finally, Amalgamated Bank grew its stake in DENTSPLY SIRONA by 57.5% during the 2nd quarter. Amalgamated Bank now owns 25,452 shares of the medical instruments supplier’s stock worth $1,650,000 after purchasing an additional 9,296 shares in the last quarter. Hedge funds and other institutional investors own 96.13% of the company’s stock.
Several research firms recently commented on XRAY. HC Wainwright cut DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and set a $68.00 target price for the company. in a research note on Thursday, November 30th. Zacks Investment Research cut DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Monday, January 8th. Stephens began coverage on DENTSPLY SIRONA in a research note on Tuesday, November 28th. They set an “overweight” rating and a $75.00 target price for the company. Credit Suisse Group cut DENTSPLY SIRONA to a “hold” rating and set a $73.00 price objective for the company. in a research report on Friday, January 5th. Finally, BidaskClub cut DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 2nd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $69.15.
DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The business’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.66 EPS. research analysts forecast that DENTSPLY SIRONA Inc will post 2.65 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, January 12th. Investors of record on Friday, December 29th were given a $0.0875 dividend. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 0.56%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is presently -10.09%.
In other news, CFO Nicholas W. Alexos bought 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average cost of $65.85 per share, with a total value of $3,292,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mark Thierer bought 77,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average cost of $66.04 per share, with a total value of $5,085,080.00. The disclosure for this purchase can be found here. 1.99% of the stock is owned by corporate insiders.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc (NASDAQ:XRAY).
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.